Payment overview · 2025
General Payments
$1,779.00
85 reported records · 19 companies
Healthcare provider profile · identity verified
Nadheer Issa, MD
Allopathic & Osteopathic Physicians|Internal Medicine · STERLING HEIGHTS, MI · NPI 1568444677
Verified facts
What the public records show
CMS Open Payments records show Nadheer Issa, MD received $1,779.00 in general payments during 2025 across 85 reported records.
Amgen Inc. accounted for 15.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 30 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Gemtesa, Jardiance, Linzess, Mounjaro, Ozempic, Rybelsus, Xifaxan.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 268 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Synthroid by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 61 claims for Prolia by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 169 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 508 claims for Jardiance by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNJARDY as an associated drug or biological on 33 records involving 33 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Synjardy by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 508 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 85 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 244 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 107 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 379 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Paxlovid by this doctor in 2024.
Salix Pharmaceuticals, a division of Bausch Health US, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XIFAXAN as an associated drug or biological on 101901 records involving 33018 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Xifaxan by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 46 claims for Gemtesa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $280.67 | 15.8% | 19 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $268.68 | 15.1% | 10 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $262.60 | 14.8% | 13 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $153.81 | 8.7% | 8 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $143.08 | 8.0% | 8 | 2025 |
| Alnylam Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $138.60 | 7.8% | 1 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $103.64 | 5.8% | 4 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $63.10 | 3.5% | 3 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $60.58 | 3.4% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $55.79 | 3.1% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $45.60 | 2.6% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $41.54 | 2.3% | 2 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $40.92 | 2.3% | 2 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $37.50 | 2.1% | 2 | 2025 |
| Radius Health, Inc. | Unresolved — no canonical attribution shown | $22.26 | 1.2% | 1 | 2025 |
| Smith+Nephew, Inc. | Unresolved — no canonical attribution shown | $16.85 | 0.9% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $16.58 | 0.9% | 1 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $13.62 | 0.8% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $13.58 | 0.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,779.00 | 85 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $262.60 | 13 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $177.17 | 6 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $173.24 | 4 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $155.46 | 12 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $153.81 | 8 | 2025 |
Source payment records
|
|||||
| AMVUTTRA Normalized: amvuttra |
Drug | Alnylam Pharmaceuticals Inc. | $138.60 | 1 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $103.64 | 4 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $103.44 | 5 | 2025 |
Source payment records
|
|||||
| KRYSTEXXA Normalized: krystexxa |
Biological | Amgen Inc. | $99.69 | 6 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $84.58 | 4 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $63.10 | 3 | 2025 |
Source payment records
|
|||||
| KEVEYIS Normalized: keveyis |
Drug | Xeris Pharmaceuticals, Inc. | $60.58 | 3 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $55.79 | 3 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $55.79 | 3 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $45.60 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $45.60 | 2 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $40.92 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $39.64 | 3 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $37.50 | 2 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $25.52 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $24.01 | 2 | 2025 |
Source payment records
|
|||||
| Tymlos Normalized: tymlos |
Drug | Radius Health, Inc. | $22.26 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $21.83 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $21.83 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $21.66 | 1 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $19.71 | 1 | 2025 |
Source payment records
|
|||||
| COLLAGENASE SANTYL Normalized: collagenase santyl |
Drug | Smith+Nephew, Inc. | $16.85 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $16.58 | 1 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $13.62 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $13.58 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 379 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 169 | exact normalized | Medicare Part D |
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 46 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 508 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 268 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 41 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 244 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 107 | exact normalized | Medicare Part D |
| XIFAXAN xifaxan |
2025 | Xifaxan | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
268 | 42 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
37 | suppressed by CMS |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
61 | 39 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
169 | 34 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
508 | 103 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | SYNJARDY open payments reported associated product |
CMS Open Payments — General Payments 33 supporting records · 33 recipient NPIs · example record 1222725005 |
Synjardy · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
508 | 103 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
41 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
85 | 12 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
244 | 43 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
107 | 30 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
379 | 68 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
17 | 17 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC Exact reporting entity; no affiliate inference |
2025 | XIFAXAN open payments reported associated product |
CMS Open Payments — General Payments 101901 supporting records · 33018 recipient NPIs · example record 1231775337 |
Xifaxan · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
46 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Metoprolol Succinate | Metoprolol Succinate | 880 | 175 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 815 | 216 |
| Levothyroxine Sodium | Levothyroxine Sodium | 786 | 151 |
| Atorvastatin Calcium | Atorvastatin Calcium | 778 | 178 |
| Losartan Potassium | Losartan Potassium | 710 | 153 |
| Omeprazole | Omeprazole | 629 | 130 |
| Amlodipine Besylate | Amlodipine Besylate | 602 | 135 |
| Metformin Hcl | Metformin Hcl | 540 | 105 |
| Jardiance | Empagliflozin | 508 | 103 |
| Simvastatin | Simvastatin | 463 | 90 |
| Lisinopril | Lisinopril | 420 | 87 |
| Metoprolol Tartrate | Metoprolol Tartrate | 415 | 86 |
| Eliquis | Apixaban | 379 | 68 |
| Bumetanide | Bumetanide | 319 | 79 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 306 | 73 |
| Alendronate Sodium | Alendronate Sodium | 290 | 56 |
| Linzess | Linaclotide | 268 | 42 |
| Allopurinol | Allopurinol | 259 | 56 |
| Diclofenac Sodium | Diclofenac Sodium | 248 | 50 |
| Tamsulosin Hcl | Tamsulosin Hcl | 247 | 56 |
| Ozempic | Semaglutide | 244 | 43 |
| Pravastatin Sodium | Pravastatin Sodium | 243 | 44 |
| Valsartan | Valsartan | 235 | 56 |
| Potassium Chloride | Potassium Chloride | 225 | 46 |
| Glimepiride | Glimepiride | 223 | 38 |
| Pantoprazole Sodium | Pantoprazole Sodium | 218 | 51 |
| Tradjenta | Linagliptin | 215 | 33 |
| Metformin Hcl Er | Metformin Hcl | 209 | 51 |
| Dexamethasone | Dexamethasone | 208 | 164 |
| Clopidogrel | Clopidogrel Bisulfate | 203 | 45 |
| Carvedilol | Carvedilol | 199 | 48 |
| Gabapentin | Gabapentin | 199 | 59 |
| Famotidine | Famotidine | 186 | 54 |
| Hydrocortisone | Hydrocortisone | 186 | 32 |
| Hydrochlorothiazide | Hydrochlorothiazide | 185 | 47 |
| Meclizine Hcl | Meclizine Hcl | 175 | 44 |
| Furosemide | Furosemide | 171 | 37 |
| Pregabalin | Pregabalin | 170 | 28 |
| Farxiga | Dapagliflozin Propanediol | 169 | 34 |
| Montelukast Sodium | Montelukast Sodium | 154 | 26 |
| Sertraline Hcl | Sertraline Hcl | 154 | 35 |
| Irbesartan | Irbesartan | 148 | 22 |
| Pioglitazone Hcl | Pioglitazone Hcl | 148 | 30 |
| Donepezil Hcl | Donepezil Hcl | 146 | 25 |
| Tramadol Hcl | Tramadol Hcl | 145 | 36 |
| Fluticasone Propionate | Fluticasone Propionate | 142 | 45 |
| Prednisone | Prednisone | 141 | 79 |
| Lovastatin | Lovastatin | 137 | 22 |
| Vascepa | Icosapent Ethyl | 137 | 19 |
| Atenolol | Atenolol | 134 | 28 |
| Hydralazine Hcl | Hydralazine Hcl | 134 | 25 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 134 | 55 |
| Azithromycin | Azithromycin | 125 | 107 |
| Ezetimibe | Ezetimibe | 125 | 28 |
| Cephalexin | Cephalexin | 122 | 98 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 121 | 28 |
| Finasteride | Finasteride | 120 | 17 |
| Nifedipine Er | Nifedipine | 119 | 26 |
| Trazodone Hcl | Trazodone Hcl | 114 | 32 |
| Alprazolam | Alprazolam | 113 | 29 |
| Doxycycline Hyclate | Doxycycline Hyclate | 113 | 93 |
| Januvia | Sitagliptin Phosphate | 110 | 18 |
| Rybelsus | Semaglutide | 107 | 30 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 103 | 19 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 103 | 18 |
| Clonazepam | Clonazepam | 102 | 26 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 100 | 21 |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 98 | 55 |
| Myrbetriq | Mirabegron | 96 | 19 |
| Xarelto | Rivaroxaban | 96 | 18 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 95 | 31 |
| Ammonium Lactate | Ammonium Lactate | 94 | 30 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 94 | 26 |
| Repaglinide | Repaglinide | 93 | 20 |
| Escitalopram Oxalate | Escitalopram Oxalate | 92 | 20 |
| Spironolactone | Spironolactone | 90 | 20 |
| Lidocaine | Lidocaine | 89 | 30 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 89 | 18 |
| Trulicity | Dulaglutide | 85 | 12 |
| Ketoconazole | Ketoconazole | 83 | 16 |
| Mirtazapine | Mirtazapine | 80 | 23 |
| Ventolin Hfa | Albuterol Sulfate | 80 | 23 |
| Repatha Sureclick | Evolocumab | 79 | 12 |
| Glipizide | Glipizide | 74 | 14 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 72 | 15 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 68 | 15 |
| Baclofen | Baclofen | 66 | 40 |
| Nitroglycerin | Nitroglycerin | 65 | 13 |
| Ibuprofen | Ibuprofen | 63 | 20 |
| Prolia | Denosumab | 61 | 39 |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 58 | 16 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 58 | 13 |
| Celecoxib | Celecoxib | 56 | 15 |
| Ipratropium Bromide | Ipratropium Bromide | 56 | 11 |
| Meloxicam | Meloxicam | 56 | 32 |
| Methylprednisolone | Methylprednisolone | 55 | 36 |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 54 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 52 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 51 | 13 |
| Breo Ellipta | Fluticasone/Vilanterol | 50 | 12 |
| Spiriva Respimat | Tiotropium Bromide | 48 | suppressed |
| Gemtesa | Vibegron | 46 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 45 | 20 |
| Ropinirole Hcl | Ropinirole Hcl | 44 | 12 |
| Calcitriol | Calcitriol | 43 | 16 |
| Valacyclovir | Valacyclovir Hcl | 43 | 13 |
| Citalopram Hbr | Citalopram Hydrobromide | 42 | suppressed |
| Mupirocin | Mupirocin | 42 | 34 |
| Clonidine Hcl | Clonidine Hcl | 41 | suppressed |
| Mounjaro | Tirzepatide | 41 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 41 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 40 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 40 | 37 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 40 | 11 |
| Colchicine | Colchicine | 39 | 20 |
| Amitriptyline Hcl | Amitriptyline Hcl | 38 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 38 | suppressed |
| Synthroid | Levothyroxine Sodium | 37 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 36 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 36 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 36 | 13 |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 35 | suppressed |
| Sotalol | Sotalol Hcl | 35 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 34 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 33 | 28 |
| Digoxin | Digoxin | 33 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 33 | 11 |
| Solifenacin Succinate | Solifenacin Succinate | 33 | suppressed |
| Methimazole | Methimazole | 32 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 31 | suppressed |
| Ondansetron Odt | Ondansetron | 31 | 22 |
| Ranolazine Er | Ranolazine | 31 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 30 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 29 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 29 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 28 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 28 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 26 | 14 |
| Neomycin-Polymyxin-Dexameth | Neomycin/Polymyxin B/Dexametha | 26 | 22 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 26 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 26 | suppressed |
| Metronidazole | Metronidazole | 25 | 22 |
| Propranolol Hcl | Propranolol Hcl | 25 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 24 | suppressed |
| Loperamide | Loperamide Hcl | 24 | 11 |
| Propranolol Hcl Er | Propranolol Hcl | 24 | suppressed |
| Bupropion Xl | Bupropion Hcl | 23 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 23 | suppressed |
| Fluconazole | Fluconazole | 23 | 19 |
| Fluticasone Propionate Hfa | Fluticasone Propionate | 22 | suppressed |
| Nystatin | Nystatin | 22 | 18 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 22 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 21 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 21 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 20 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 19 | suppressed |
| Alcohol Swabs | Alcohol Antiseptic Pads | 18 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 18 | 11 |
| Levetiracetam | Levetiracetam | 18 | suppressed |
| Novolog Flexpen | Insulin Aspart | 18 | suppressed |
| Procto-Med Hc | Hydrocortisone | 18 | suppressed |
| Zafirlukast | Zafirlukast | 18 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 17 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 17 | 17 |
| Primidone | Primidone | 17 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 17 | 14 |
| Torsemide | Torsemide | 17 | suppressed |
| Alcohol Swab | Alcohol Antiseptic Pads | 16 | suppressed |
| Nystatin-Triamcinolone | Nystatin/Triamcinolone Acet | 16 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 16 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 16 | suppressed |
| Verapamil Er | Verapamil Hcl | 16 | suppressed |
| Brilinta | Ticagrelor | 15 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 15 | suppressed |
| Lactulose | Lactulose | 15 | suppressed |
| Metolazone | Metolazone | 15 | suppressed |
| Synjardy | Empagliflozin/Metformin Hcl | 15 | suppressed |
| Aliskiren | Aliskiren Hemifumarate | 14 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 14 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 14 | suppressed |
| Lamotrigine | Lamotrigine | 14 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 14 | suppressed |
| Sucralfate | Sucralfate | 14 | suppressed |
| Telmisartan | Telmisartan | 14 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 13 | suppressed |
| Klor-Con M20 | Potassium Chloride | 13 | suppressed |
| Lansoprazole | Lansoprazole | 13 | suppressed |
| Lidocaine-Prilocaine | Lidocaine/Prilocaine | 13 | suppressed |
| Memantine Hcl | Memantine Hcl | 13 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 12 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 12 | suppressed |
| Entresto | Sacubitril/Valsartan | 12 | suppressed |
| Fluvastatin Er | Fluvastatin Sodium | 12 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 12 | suppressed |
| Jentadueto Xr | Linagliptin/Metformin Hcl | 12 | suppressed |
| Prasugrel Hcl | Prasugrel Hcl | 12 | suppressed |
| Xifaxan | Rifaximin | 12 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 11 | suppressed |
| Glipizide Er | Glipizide | 11 | suppressed |
| Levalbuterol Tartrate Hfa | Levalbuterol Tartrate | 11 | suppressed |
| Levofloxacin | Levofloxacin | 11 | 11 |
| Lidocaine Hcl Viscous | Lidocaine Hcl | 11 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 11 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 11 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 11 | suppressed |
| Zenpep | Lipase/Protease/Amylase | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,779.00 · 85 records | Amgen Inc. | AIRSUPRA, AMVUTTRA, BREZTRI, COLLAGENASE SANTYL, ELIQUIS, EVENITY, FARXIGA, FREESTYLE LIBRE 3, GEMTESA, IBSRELA, JARDIANCE, KEVEYIS, KRYSTEXXA, Korlym, LINZESS, MOUNJARO, NEXLETOL, NURTEC ODT, OTEZLA, Ozempic, QULIPTA, REPATHA, Rybelsus, TZIELD, Tymlos, UBRELVY, VOQUEZNA, Wegovy, XIFAXAN, ZEPBOUND | 16 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error